In Brief Robert Califf’s confirmation as FDA commissioner clears Senate HELP Committee January 14, 2022Vol.48 No.02
Drugs & Targets FDA grants fast track designation for enobosarm in AR+ ER+ HER2- metastatic breast cancer January 14, 2022Vol.48 No.02
Drugs & Targets FDA clears IND for P-MUC1C-ALLO1, a fully allogeneic CAR T targeting multiple solid tumors January 07, 2022Vol.48 No.01
Drugs & Targets FDA grants Breakthrough Therapy designation for CLN-081 in locally advanced or metastatic EGFR-mutated NSCLC January 07, 2022Vol.48 No.01
Drugs & Targets FDA grants Fast Track designation for Reqorsa with Keytruda in NSCLC January 07, 2022Vol.48 No.01
Drugs & TargetsFree FDA approves Orencia for prevention of acute graft vs. host disease following unrelated donor HSCT December 17, 2021Vol.47 No.46
Drugs & Targets FDA approves Rituxan plus chemo for pediatric cancer indications December 10, 2021Vol.47 No.45
Drugs & Targets FDA approves FoundationOne CDx as companion diagnostic for BRAF inhibitor therapeutics in melanoma December 10, 2021Vol.47 No.45
Drugs & Targets FDA approves Oncomine Dx Target Test as CDx for Rybrevant December 10, 2021Vol.47 No.45
